Table 4.
Variables | Univariate cox analysis results | Multi-factor cox analysis results | ||||
---|---|---|---|---|---|---|
HR | 95% CI of HR | P-value | HR | 95% CI of HR | P-value | |
PFS | ||||||
Age | 0.984 | 0.966–1.003 | 0.102 | |||
Gender (female) | 1.54 | 0.896–2.645 | 0.118 | 1.887 | 1.029–3.462 | 0.04* |
Alcohol intake (non) | 1.214 | 0.851–1.731 | 0.285 | |||
MELD score | 1.154 | 0.970–1.371 | 0.105 | 1.292 | 1.054–1.582 | 0.014* |
Maximal lesion diameter (≥3cm) | 1.283 | 0.786–2.095 | 0.319 | 2.592 | 1.223–5.493 | 0.013* |
TB | 0.994 | 0.979–1.010 | 0.459 | |||
Albumin | 1.006 | 0.996–1.016 | 0.249 | |||
Creatinine | 0.996 | 0.979–1.012 | 0.616 | |||
INR | 1.454 | 1.056–2.001 | 0.022* | |||
Noninvade | 0.378 | 0.197–0.727 | 0.004* | |||
Blood-supply (poor) | 1.141 | 0.935–1.392 | 0.193 | 1.258 | 0.994–1.593 | 0.057 |
Portal invasion | 1.539 | 0.749–3.161 | 0.24 | |||
AFP (≥20) | 1.077 | 0.725–1.600 | 0.714 | |||
Child-Pugh grade (B) | 1.879 | 0.862–4.099 | 0.113 | |||
PA-TACE | 0.293 | 0.202–0.425 | <0.001* | 0.293 | 0.179–0.481 | <0.001* |
OS | ||||||
Age | 0.988 | 0.954–1.023 | 0.494 | |||
Gender (female) | 1.896 | 0.790–4.553 | 0.152 | |||
Alcohol intake (non) | 1.095 | 0.573–2.093 | 0.783 | |||
MELD score | 1.459 | 0.968–2.198 | 0.071 | |||
Maximal lesion diameter (≥3cm) | 1.39 | 0.539–2.587 | 0.496 | |||
TB | 1.005 | 0.982–1.028 | 0.682 | |||
Albumin | 0.999 | 0.982–1.016 | 0.87 | |||
Creatinine | 0.996 | 0.967–1.025 | 0.77 | |||
INR | 0.906 | 0.497–1.652 | 0.747 | |||
Noninvade | 0.716 | 0.219–2.335 | 0.579 | |||
Blood-supply (poor) | 1.37 | 0.905–2.075 | 0.137 | 1.861 | 1.006–3.443 | 0.048* |
Portal invasion | 1.737 | 0.533–5.660 | 0.36 | |||
AFP (≥20) | 1.321 | 0.640–2.728 | 0.452 | 2.363 | 0.913–6.113 | 0.076 |
Child-Pugh grade (B) | 1.94 | 0.579–6.506 | 0.283 | |||
PA-TACE | 0.164 | 0.074–0.360 | <0.001* | 0.159 | 0.047–0.537 | 0.003* |
Note: *Significant difference (P<0.05).
Abbreviations: AFP, α-fetoprotein; INR, international normalized ratio; OS, overall survival; PA-TACE, postoperative adjuvant TACE; PFS, progress-free survival; TB, total bilirubin; MELD, Model of End-Stage Liver Disease.